The disruption of the TGF-β signalling, either pharmacologically or genetically, may reduce the formation of ovarian cancer metastases on the omentum, highlighting the role of the TGF-β signaling system in supporting tumor cells’ omental metastatic capacity [35, 62, 63]. The gene discussed is TGFB1; the disease is ovarian cancer.